Norcantharidin | CAS#29745-04-8 | anticancer

MedKoo Cat#: 584443 | Name: Norcantharidin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.

Chemical Structure

Norcantharidin

CAS#29745-04-8 (free base)

Theoretical Analysis

MedKoo Cat#: 584443

Name: Norcantharidin

CAS#: 29745-04-8 (free base)

Chemical Formula: C8H8O4

Exact Mass: 168.0423

Molecular Weight: 168.15

Elemental Analysis: C, 57.14; H, 4.80; O, 38.06

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 310.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

17439-94-0 (diammonium) 129-67-9 (disodium) 29745-04-8 (free base)

Synonym

Norcantharidin; Endothall anhydride

IUPAC/Chemical Name

4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-, (3a-alpha,4-beta,7-beta,7a-alpha)-

InChi Key

JAABVEXCGCXWRR-FBXFSONDSA-N

InChi Code

InChI=1S/C8H8O4/c9-7-5-3-1-2-4(11-3)6(5)8(10)12-7/h3-6H,1-2H2/t3-,4+,5-,6+

SMILES Code

O=C1OC([C@]2([H])[C@@](O3)([H])CC[C@@]3([H])[C@@]21[H])=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.

In vitro activity:

NCTD (norcantharidin) induced cell cycle arrest at G2/M phase in both cell lines. The early and late apoptosis was also observed. Further investigation indicated that NCTD suppressed not only the expression of the total EGFR and the phosphorylated EGFR but also the expression of the total c-Met and the phosphorylated c-Met in colon cancer cells. Reference: BMC Cancer. 2017 Jan 13;17(1):55. https://pubmed.ncbi.nlm.nih.gov/28086832/

In vivo activity:

The tumor xenograft model of human gallbladder carcinoma in nude mice in vivo was established with subcutaneous GBC-SD cells. The experimental mice were randomly divided into control, 5-FU, NCTD (norcantharidin), and NCTD+5-FU groups which were given different treatments. NCTD inhibited the growth of the xenografted tumors in a dose- and time-dependent manner. Tumor volume decreased (5.61+/-0.39 vs. 9.78+/-0.61 cm3, P=0.000) with an increased tumor inhibitory rate (42.63% vs. 0%, P=0.012) in the NTCD group compared with the control group. Reference: Hepatobiliary Pancreat Dis Int. 2010 Aug;9(4):414-22. https://pubmed.ncbi.nlm.nih.gov/20688607/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	178.41
	DMSO	31.5	187.33
	Ethanol	1.0	5.95

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 168.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Schöpe PC, Zinnow V, Ishfaq MA, Smith J, Herrmann P, Shoemaker RH, Walther W, Stein U. Cantharidin and Its Analogue Norcantharidin Inhibit Metastasis-Inducing Genes S100A4 and MACC1. Int J Mol Sci. 2023 Jan 7;24(2):1179. doi: 10.3390/ijms24021179. PMID: 36674695; PMCID: PMC9866560. 2. Qiu P, Wang S, Liu M, Ma H, Zeng X, Zhang M, Xu L, Cui Y, Xu H, Tang Y, He Y, Zhang L. Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells. BMC Cancer. 2017 Jan 13;17(1):55. doi: 10.1186/s12885-016-3039-x. PMID: 28086832; PMCID: PMC5237309. 3. Yang G, Xu H, Yao M, Yan S, Wu M, Zhou C. Norcantharidin ameliorates estrogen deficient-mediated bone loss by attenuating the activation of extracellular signal-regulated kinase/ROS/NLRP3 inflammasome signaling. Front Pharmacol. 2022 Nov 3;13:1019478. doi: 10.3389/fphar.2022.1019478. PMID: 36408264; PMCID: PMC9669383. 4. Fan YZ, Zhao ZM, Fu JY, Chen CQ, Sun W. Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo. Hepatobiliary Pancreat Dis Int. 2010 Aug;9(4):414-22. PMID: 20688607.

In vitro protocol:

In vivo protocol:

1. Yang G, Xu H, Yao M, Yan S, Wu M, Zhou C. Norcantharidin ameliorates estrogen deficient-mediated bone loss by attenuating the activation of extracellular signal-regulated kinase/ROS/NLRP3 inflammasome signaling. Front Pharmacol. 2022 Nov 3;13:1019478. doi: 10.3389/fphar.2022.1019478. PMID: 36408264; PMCID: PMC9669383. 2. Fan YZ, Zhao ZM, Fu JY, Chen CQ, Sun W. Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo. Hepatobiliary Pancreat Dis Int. 2010 Aug;9(4):414-22. PMID: 20688607.

[1] Qiu P, et al. BMC Cancer. 2017, 17(1):55. [2] Fan YZ, et al. Hepatobiliary Pancreat Dis Int. 2010, 9(4):414